India Bears Nearly 70% of South Asia’s Childhood Cancer Burden, Landmark Lancet Study Reveals

NEW DELHI — India accounts for nearly seven out of every 10 childhood cancer diagnoses in South Asia, exposing profound regional inequities in diagnostic access, treatment availability, and survival outcomes.

According to a landmark report from the Global Burden of Disease (GBD) 2023 Study published in The Lancet, an estimated 37,716 children aged 0–14 years were diagnosed with cancer across South Asian Association for Regional Cooperation (SAARC) nations in 2022, leading to 17,698 deaths. India alone bore the majority of this crisis, contributing 25,939 new cases—68.8% of the subregional total—and claiming approximately 17,000 young lives in 2023.

Key Findings: A Disproportionate Global Burden

The GBD analysis emphasizes that paediatric cancer remains overwhelmingly concentrated in low- and middle-income countries (LMICs). Worldwide, 85% of new paediatric cases and 94% of related deaths occur in these settings. South Asia alone accounts for one in every five childhood cancer deaths globally.

       2022 South Asian Paediatric Cancer Burden (Ages 0–14)
┌─────────────────────────┬──────────────────┬─────────────────┐
│ Country                 │ New Cases        │ Share of Total  │
├─────────────────────────┼──────────────────┼─────────────────┘
│ India                   │ 25,939           │ 68.8%           │
│ Pakistan                │  7,841           │ 20.8%           │
│ Remaining SAARC Nations │  3,936           │ 10.4%           │
└─────────────────────────┴──────────────────┴─────────────────┘

In India, cancer rose to become the 10th leading cause of death among children in 2023. For global context, China reported 16,000 paediatric cancer deaths in the same period, while Nigeria and Pakistan recorded roughly 9,000 each.

Common Malignancies

Across all SAARC nations, leukaemia proved to be the most widespread diagnosis, accounting for 35% to 50% of all national childhood cases. Other primary drivers of paediatric cancer mortality and morbidity include:

• Brain and Central Nervous System (CNS) Tumours

• Lymphomas (Hodgkin and non-Hodgkin)

• Solid Tumours (such as neuroblastoma and Wilms tumour)

Expert Perspectives: “Highly Curable, Yet Deadly”

Medical specialists emphasize that unlike many adult malignancies, most paediatric cancers respond exceptionally well to treatment when caught early.

“Childhood cancers are highly curable—offering a profound opportunity for investment,” says Professor Manas Kalra, a paediatric haematologist and oncologist at Sir Ganga Ram Hospital in Delhi. He notes that while 50,000 to 75,000 children are estimated to develop cancer annually in India, underreporting remains a significant challenge.

The stark global disparity in outcomes stems not from biological differences, but from healthcare infrastructure.

“While outcomes for many childhood cancers have improved in high-income countries, these gains have not been equitably shared,” explains Dr. Lisa Force, lead author of the study from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington School of Medicine. She attributes this gap to diagnostic delays, lack of essential medications, and systemic barriers in resource-limited settings.

Despite these hurdles, clinical success is achievable within specialized care centers. Dr. R. Seth, a leading researcher involved in India’s first national childhood cancer survivorship study, highlights recent tracking data:

“For years, the focus was only on acute care—that children should survive. But what happens after treatment ends has, until now, remained largely undocumented.” That national registry study, published in The Lancet Regional Health – Southeast Asia, tracked over 5,400 survivors across 20 Indian tertiary centers and demonstrated a encouraging five-year overall survival rate of 94.5%.

Context and Background: Understanding the Numbers

To measure the full impact of disease, epidemiologists utilize Disability-Adjusted Life Years (DALYs)—a metric where one DALY represents the loss of the equivalent of one year of full health.

In 2023, paediatric cancer resulted in 11.7 million DALYs globally, with 94% of that burden concentrated in LMICs. Between 1990 and 2023, while global paediatric cancer deaths dropped by 27%, childhood cancer remained the eighth-leading cause of death worldwide among children, claiming more lives globally than measles, tuberculosis, or HIV/AIDS.

What Drives India’s High Numbers?

Several factors contribute to India’s substantial share of the regional total:

1. Demographics: India maintains a massive paediatric population, with individuals under 35 years old comprising over 65% of the country’s population.

2. Gender Disparities: Boys account for roughly 60% of reported cases across SAARC nations. Experts indicate this does not reflect a biological predisposition, but rather societal biases where families are more likely to seek specialized medical care for male children.

3. Registry Coverage gaps: Population-based cancer registries remain concentrated in urban centers, leaving rural incidence rates under-documented.

Public Health Implications: The Path Forward

Addressing these outcomes requires structural reforms across primary and tertiary healthcare networks. Authors of the report advocate for aligning regional efforts with the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) targets.

Key recommendations include:

• Strengthening Referral Pathways: Training primary care providers to identify early warning signs of childhood malignancy.

• Workforce Expansion: Increasing the number of trained paediatric oncologists, specialized nurses, and pathologists.

• Equitable Resource Access: Ensuring steady access to essential chemotherapy agents, surgical oncology, and radiotherapy facilities.

• Expanding Registries: Establishing robust population-based cancer registration systems to track true incidence and outcome metrics.

Professor Kalra advocates for a unified national response: “A concerted effort by all stakeholders can hugely impact the outcomes. These young survivors can grow into thriving, productive contributors to our nation’s future.”

Study Limitations and Data Nuances

While the GBD 2023 study provides critical insights, researchers highlight important limitations within the data:

• Underdiagnosis vs. True Incidence: India’s reported paediatric cancer incidence rate (80–90 per 100,000 children) appears significantly lower than rates in North America and Western Europe (approx. 160 per 100,000). Rather than a lower underlying risk, experts attribute this gap to missed diagnoses and unregistered cases in rural areas.

• Population Scale Effects: India’s sheer demographic volume means even a modest incidence rate results in high absolute case counts, requiring careful interpretation when comparing metrics against smaller neighboring states.

Practical Takeaways for Families

For parents and caregivers, early detection remains the most critical factor in successful treatment. Healthcare providers advise seeking prompt medical evaluation if a child exhibits persistent, unexplained symptoms.

Signs to Monitor:

• Unexplained, prolonged fever or recurrent infections

• Sudden, unintentional weight loss or loss of appetite

• Persistent pain in bones, joints, or back

• Unusual lumps, swellings, or mass anywhere on the body

• Frequent headaches, often accompanied by early-morning vomiting

• Unexplained bruising, bleeding, or noticeable paleness

While advanced treatment centers achieve high survival rates, navigating a diagnosis requires coordinated care. Advocacy groups continue to push for incorporating basic childhood cancer screening into routine community health programs to ensure every family—regardless of geography or economic status—receives timely care.

References

1. https://www.deccanherald.com/health/healthcare/india-accounts-for-nearly-7-out-of-10-childhood-cancer-cases-in-south-asia-lancet-study-4091615

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.